SecBot SecBot
8-K ·Filed Sep 9, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001193125-26-385881
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The spin-out of Kura's menin inhibitor program for diabetes into a separately funded subsidiary (Caspian) with $50M in new capital is a clear value-unlocking event. It de-risks the cardiometabolic pipeline by securing non-dilutive funding and allows Kura to focus on its core oncology programs (ziftomenib). The ~49.2% retained stake provides upside optionality. Monitor for future Caspian milestones (IND, clinical data) and any potential IPO or partnership that could crystallize value for Kura shareholders.

DirectionBullish
Confidencehigh
Horizonweeks

KOMZIFTI

◆ Mixed Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available in the U.S. since November 2025.
Next catalyst
None dated

What to watchKOMZIFTI is already approved and generating growing revenue, so the defining binary event has passed. Watch for ASH 2026 (December 2026) where ziftomenib combination data in newly diagnosed AML will be presented -- strong data could support a major label-expansion opportunity into the frontline setting, while weak data would cap the upside thesis. Also track quarterly sales growth trajectory as the key near-term value driver.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$12.09
T+0 close · Sep 9, 2026 · via day close
Latest settled
−11.75%
T+20 · $10.67 · next T+60 in 16d
Vs SPY
−13.94%
α at T+20
Latest observation
−32.09%
T+46 · FF3 residual α
  1. T+0 · Sep 9 $12.09entry
  2. T+1 · 2mo ago −4.30%α −3.70% · $11.57
  3. T+5 · 2mo ago −6.00%α −5.66% · $11.37
  4. T+20 · 6w ago −11.75%α −13.94% · $10.67
  5. T+48 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. Caspian raised $50.0M in a Series A preferred stock private financing, with Kura investing $4.3M, leaving Kura with ~49.2% ownership. Kura contributed assets including KO-7246 and related IP to Caspian in exchange for Caspian common stock and a $1.5M reimbursement, and entered into an intercompany services agreement. This spin-out of a non-core pipeline asset into a separately capitalized entity is a positive catalyst, unlocking value from Kura's menin platform beyond oncology without diluting Kura shareholders.

Key Facts

  • Kura formed subsidiary Caspian Therapeutics to develop next-gen menin inhibitors for diabetes/cardiometabolic diseases.
  • Caspian raised $50.0M in Series A preferred stock financing; Kura invested $4.3M.
  • Kura retains ~49.2% ownership of Caspian post-financing.
  • Kura contributed assets including KO-7246 and related IP to Caspian for shares and up to $1.5M reimbursement.
  • Kura granted Caspian non-exclusive licenses to ziftomenib patents/data for the Caspian field; Caspian granted Kura a reciprocal license.
  • Kura and Caspian entered an intercompany services agreement for R&D and administrative services.

Financial Impact

Caspian raised $50.0M in external capital; Kura invested $4.3M and retains ~49.2% ownership. Kura received up to $1.5M reimbursement for prior maintenance costs.

non-dilutive financing for subsidiaryownership stakereimbursement

Risk Factors

  • Caspian is a separate entity with its own governance; Kura does not control it fully.
  • Development of menin inhibitors for diabetes is early-stage and carries clinical risk.
  • The intercompany services agreement creates ongoing operational complexity and potential conflicts of interest.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-385881
Document: 0001193125-26-385881-index-headers.html0001193125-26-385881
Document: 0001193125-26-385881-index.html0001193125-26-385881
Document: 0001193125-26-385881.txt0001193125-26-385881

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Viewing Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026